Karyopharm Therapeutics (KPTI) Profit After Tax (2012 - 2025)

Karyopharm Therapeutics has reported Profit After Tax for 14 years, with the latest figure at -$102.2 million in Q4 2025.

• For the quarter ending Q4 2025, Profit After Tax fell 232.03% year-over-year to -$102.2 million; the trailing twelve-month figure through Dec 2025 stood at -$196.0 million (down 156.52% YoY), and the FY2025 full-year result was -$196.0 million, down 156.52% from the prior year.
• Profit After Tax for Q4 2025 stood at -$102.2 million, down from -$33.1 million in the prior quarter.
• The five-year high for Profit After Tax was $38.7 million in Q4 2021, with the low at -$102.2 million in Q4 2025.
• Historically, Profit After Tax has averaged -$35.2 million across 5 years, with a median of -$36.8 million in 2022.
• Annual changes were most pronounced in 2021 — Profit After Tax soared 189.17% — and 2025, when it slumped 256.57%.
• Karyopharm Therapeutics' Profit After Tax stood at $38.7 million in 2021, then plunged by 199.45% to -$38.5 million in 2022, then dropped by 8.65% to -$41.8 million in 2023, then gained by 26.43% to -$30.8 million in 2024, then sank by 232.03% to -$102.2 million in 2025.
• The last three Profit After Tax figures came in at -$102.2 million (Q4 2025), -$33.1 million (Q3 2025), and -$37.3 million (Q2 2025), per Business Quant data.